Despite occasional findings that some modified peptides may not always be recognized by tumor-reactive T cells [36], sequence modifications both within the epitope and in flanking residues have been useful in increasing immunogenicity in many cases, by affecting MHC binding or antigen processing [3], [7], [23], [37], [38]. This evidence concerns the gene HLA-C and neoplasm.